X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1400) 1400
science & technology (1341) 1341
life sciences & biomedicine (1278) 1278
azacitidine - analogs & derivatives (773) 773
male (760) 760
female (754) 754
azacitidine - administration & dosage (745) 745
oncology (719) 719
azacitidine - pharmacology (584) 584
azacitidine - therapeutic use (564) 564
aged (552) 552
hematology (549) 549
middle aged (545) 545
animals (466) 466
myelodysplastic syndromes - drug therapy (415) 415
dna methylation (376) 376
adult (365) 365
treatment outcome (359) 359
azacitidine (345) 345
decitabine (327) 327
azacitidine - adverse effects (306) 306
leukemia, myeloid, acute - drug therapy (292) 292
antimetabolites, antineoplastic - therapeutic use (287) 287
aged, 80 and over (283) 283
cancer (281) 281
dna methylation - drug effects (278) 278
mice (276) 276
cell line, tumor (253) 253
methylation (250) 250
antineoplastic combined chemotherapy protocols - therapeutic use (243) 243
myelodysplastic syndromes (229) 229
antimetabolites, antineoplastic - administration & dosage (216) 216
leukemia (206) 206
research (204) 204
myelodysplastic syndrome (190) 190
care and treatment (189) 189
epigenetics (179) 179
gene expression (179) 179
acute myeloid leukemia (178) 178
dose-response relationship, drug (159) 159
analysis (158) 158
drug administration schedule (154) 154
antineoplastic agents (150) 150
chemotherapy (150) 150
hematology, oncology and palliative medicine (148) 148
antimitotic agents (146) 146
antimetabolites, antineoplastic - adverse effects (145) 145
deoxyribonucleic acid--dna (137) 137
prognosis (137) 137
antimetabolites, antineoplastic - pharmacology (133) 133
genetic aspects (130) 130
pharmacology & pharmacy (129) 129
medicine & public health (128) 128
dna (124) 124
health aspects (124) 124
abridged index medicus (118) 118
dna modification methylases - antagonists & inhibitors (118) 118
remission induction (116) 116
cell biology (114) 114
myelodysplastic syndromes - mortality (114) 114
gene expression regulation, neoplastic - drug effects (112) 112
antineoplastic agents - therapeutic use (108) 108
stem cells (107) 107
apoptosis (104) 104
drug therapy (104) 104
time factors (104) 104
leukemia, myeloid, acute - mortality (102) 102
myelodysplastic syndromes - genetics (102) 102
retrospective studies (100) 100
enzyme inhibitors - pharmacology (99) 99
rats (99) 99
transplantation (98) 98
antineoplastic combined chemotherapy protocols - adverse effects (97) 97
cell proliferation - drug effects (97) 97
promoter regions, genetic (96) 96
5-aza-2'-deoxycytidine (95) 95
apoptosis - drug effects (95) 95
clinical trials as topic (93) 93
epigenesis, genetic (92) 92
myelodysplastic syndromes - pathology (92) 92
adolescent (91) 91
survival analysis (90) 90
tumors (90) 90
biochemistry & molecular biology (89) 89
research article (89) 89
patients (88) 88
5-azacytidine (87) 87
genes (87) 87
risk factors (87) 87
leukemia, myeloid, acute - pathology (86) 86
epigenesis, genetic - drug effects (85) 85
medicine, research & experimental (84) 84
research & experimental medicine (84) 84
survival rate (84) 84
drug synergism (83) 83
leukemia, myeloid, acute - genetics (82) 82
disease-free survival (81) 81
myelodysplastic syndromes - therapy (80) 80
hemic and lymphatic diseases (78) 78
drug therapy, combination (77) 77
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1736) 1736
Chinese (17) 17
Japanese (12) 12
Russian (5) 5
German (4) 4
Spanish (4) 4
French (3) 3
Portuguese (3) 3
Italian (2) 2
Hebrew (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of controlled release, ISSN 0168-3659, 12/2017, Volume 268, pp. 92 - 101
Myelodysplastic syndromes (MDS) are a diverse group of bone marrow disorders and clonal hematopoietic stem cell disorders characterized by abnormal blood... 
Bone marrow | Decitabine | Arsenic trioxide | Delivery | Nanoparticle | Myelodysplastic syndrome | Pharmacology & Pharmacy | Physical Sciences | Chemistry | Life Sciences & Biomedicine | Chemistry, Multidisciplinary | Science & Technology | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Nanoparticles - chemistry | Apoptosis - drug effects | Oxides - chemistry | Azacitidine - chemistry | Phosphatidylethanolamines - therapeutic use | Polyethylene Glycols - chemistry | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Polyethylene Glycols - therapeutic use | Alendronate - chemistry | Alendronate - therapeutic use | Tissue Distribution | Arsenicals - therapeutic use | Nanoparticles - therapeutic use | Bone and Bones - metabolism | Phosphatidylethanolamines - pharmacokinetics | Bone Marrow Cells - drug effects | Antineoplastic Agents - pharmacokinetics | Arsenicals - pharmacokinetics | Alendronate - pharmacokinetics | Myelodysplastic Syndromes - drug therapy | Oxides - administration & dosage | Azacitidine - administration & dosage | Oxides - therapeutic use | Cell Survival - drug effects | Arsenic Trioxide | Azacitidine - pharmacokinetics | Myelodysplastic Syndromes - metabolism | Cells, Cultured | Polyethylene Glycols - pharmacokinetics | Azacitidine - analogs & derivatives | Mice, Transgenic | Phosphatidylethanolamines - administration & dosage | Antineoplastic Agents - chemistry | Polyethylene Glycols - administration & dosage | Oxides - pharmacokinetics | Arsenicals - administration & dosage | Animals | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Arsenicals - chemistry | Nanoparticles - administration & dosage | Phosphatidylethanolamines - chemistry | Alendronate - administration & dosage | Azacitidine - therapeutic use | Medical research | Medical colleges | Medical examination | Arsenic | Analysis | Medicine, Experimental | Hematopoietic stem cells | Blood | Index Medicus | delivery | nanoparticle | decitabine | arsenic trioxide | bone marrow
Journal Article
Journal Article
British journal of haematology, ISSN 0007-1048, 11/2014, Volume 167, Issue 3, pp. 356 - 365
Summary To test the safety and activity of 5‐aza‐2′‐deoxycytidine (decitabine) in patients with relapsed/refractory acute lymphocytic leukaemia (ALL), we... 
clinical trial | DNA methylation | decitabine | precursor cell lymphoblastic leukaemia‐Lymphoma | Clinical trial | Decitabine | Precursor cell lymphoblastic leukaemia-Lymphoma | Life Sciences & Biomedicine | Hematology | Science & Technology | Recurrence | Azacitidine - adverse effects | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Child, Preschool | Dexamethasone - adverse effects | Male | Cytarabine - adverse effects | Cyclophosphamide - adverse effects | DNA, Neoplasm - chemistry | Antimetabolites, Antineoplastic - administration & dosage | Young Adult | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Hyperglycemia - chemically induced | Vincristine - administration & dosage | Adult | Female | Child | Chemical and Drug Induced Liver Injury - etiology | Azacitidine - administration & dosage | Doxorubicin - administration & dosage | Dexamethasone - administration & dosage | Drug Administration Schedule | Kaplan-Meier Estimate | Azacitidine - analogs & derivatives | Remission Induction | Cytarabine - administration & dosage | Methotrexate - adverse effects | Antimetabolites, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Bone Marrow - pathology | Adolescent | Antimetabolites, Antineoplastic - adverse effects | Vincristine - adverse effects | Methotrexate - administration & dosage | Aged | Infusions, Intravenous | DNA Methylation - drug effects | Doxorubicin - adverse effects | Gastrointestinal Diseases - chemically induced | Azacitidine - therapeutic use | Index Medicus | DNA Methylation | Precursor Cell Lymphoblastic Leukaemia-Lymphoma | Clinical Trial
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 07/2012, Volume 30, Issue 21, pp. 2670 - 2677
Journal Article
Proceedings of the National Academy of Sciences - PNAS, ISSN 1091-6490, 07/2014, Volume 111, Issue 32, pp. 11774 - 11779
Impressive responses have been observed in patients treated with checkpoint inhibitory anti-programmed cell death-1 (PD-1) or anticytotoxic... 
T lymphocytes | Tumor cell line | Myeloid cells | Medical treatment | Antibodies | Epigenetics | Cellular immunity | Mice | Tumors | Cancer | Exome | 5-azacytidine | Entinostat | Methyltransferase | HDAC | Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Mammary Neoplasms, Experimental - immunology | Immunotherapy - methods | Humans | Histone Deacetylase Inhibitors - administration & dosage | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Benzamides - administration & dosage | Colorectal Neoplasms - therapy | Neoplasm Metastasis - immunology | Myeloid Cells - immunology | Female | Myeloid Cells - drug effects | Epigenesis, Genetic - drug effects | Mammary Neoplasms, Experimental - secondary | Azacitidine - administration & dosage | Neoplasm Metastasis - therapy | Pyridines - administration & dosage | Combined Modality Therapy | CTLA-4 Antigen - immunology | Mammary Neoplasms, Experimental - therapy | Neoplasm Metastasis - genetics | Animals | Colorectal Neoplasms - immunology | Antibodies, Monoclonal - administration & dosage | Cell Line, Tumor | Colorectal Neoplasms - secondary | Mice, Inbred BALB C | Programmed Cell Death 1 Receptor - immunology | CTLA-4 Antigen - antagonists & inhibitors | Index Medicus | Biological Sciences | methyltransferase | exome | entinostat
Journal Article
Blood, ISSN 1528-0020, 09/2018, Volume 132, Issue 11, pp. 1125 - 1133
Journal Article
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 06/2011, Volume 29, Issue 18, pp. 2521 - 2527
Journal Article